{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:32:40Z","timestamp":1789889560843,"version":"4.0.1"},"reference-count":224,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is characterized by high metastatic potential, frequent recurrence and limited targeted regimens. The chemokine network acts as a central orchestrator, reshaping its tumor immune microenvironment (TIME) and determining therapeutic responsiveness. Yet its clinical translation remains hindered by network complexity and insufficient patient stratification. In this review, we systematically synthesize current evidence on how chemokine networks regulate key TIME component (macrophages, T cells, cancer-associated fibroblasts, myeloid-derived suppressor cells, and cancer stem cells) to drive TNBC progression, metastasis, and therapeutic resistance. We also critically evaluate chemokine-targeted interventions, spanning preclinical candidates (small-molecule inhibitors, monoclonal antibodies, miRNA-based therapies, natural products, and nanocarrier systems) to clinical-stage agents. A critical gap emerges from this evaluation: although numerous chemokine axes demonstrate robust preclinical efficacy, most clinical trials have yielded negative or marginal results. These failures are largely attributable to target redundancy, the absence of subtype-specific biomarkers, and suboptimal combination strategies. Based on recent research advances, we propose a three-pillar framework for future therapeutic success: precision subtyping-guided target selection, rational combination regimens (particularly with immune checkpoint inhibitors), and iterative biomarker validation. Overall, this review provides a roadmap for navigating chemokine network complexity, distilling actionable insights for clinical translation, and defining priority research directions to overcome current bottlenecks in TNBC chemokine-targeted therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1883663","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:33:48Z","timestamp":1785933228000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Wanyu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanbin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"218556","DOI":"10.1016\/j.canlet.2026.218556","article-title":"Challenges in triple negative breast cancer treatment and therapeutic potential of the mitogen activated protein kinase pathway","volume":"653","author":"Nand","year":"2026","journal-title":"Cancer Lett"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/1043-4666(91)90013-4","article-title":"Biology of the RANTES\/SIS cytokine family","volume":"3","author":"Schall","year":"1991","journal-title":"Cytokine"},{"key":"B6","article-title":"Two burgeoning families of platelet factor 4-related proteins: mediators of the inflammatory response","volume":"2","author":"Stoeckle","year":"1990","journal-title":"New Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci114265","article-title":"Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils","volume":"84","author":"Baggiolini","year":"1989","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.3.14.2687068","article-title":"Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines","volume":"3","author":"Wolpe","year":"1989","journal-title":"FASEB J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115318","article-title":"The role of CCL2\/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine","volume":"209","author":"Pozzi","year":"2024","journal-title":"Adv Drug Delivery Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.4049\/jimmunol.150.11.4996","article-title":"Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines","volume":"150","author":"Widmer","year":"1993","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/347669a0","article-title":"Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES","volume":"347","author":"Schall","year":"1990","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.143.9.2907","article-title":"A novel polypeptide secreted by activated human T lymphocytes","volume":"143","author":"Miller","year":"1989","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0167-5699(89)90085-6","article-title":"The cytokine network","volume":"10","author":"Balkwill","year":"1989","journal-title":"Immunol Today"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601756","article-title":"Chemokines: humble yet mighty players in the tumour microenvironment","volume":"16","author":"Xavier","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1006828","article-title":"Roles of chemokines in influencing tumor microenvironment in breast cancer","volume-title":"New Updates in Tumor Microenvironment","author":"Son","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"Bule","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1779388","article-title":"Targeting the chemokine-Treg axes in tumor immune evasion: from mechanisms to therapeutic opportunities","volume":"17","author":"Lian","year":"2026","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571194","article-title":"Anti-CXCR4 single-chain variable fragment antibodies have anti-tumor activity","volume":"10","author":"Liang","year":"2020","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5230","article-title":"Upregulation of microRNA-181b inhibits CCL18-induced breast cancer cell metastasis and invasion via the NF-kappaB signaling pathway","volume":"12","author":"Wang","year":"2016","journal-title":"Oncol Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01294","article-title":"Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis","volume":"9","author":"Shanmugam","year":"2018","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27293","article-title":"The chemokine system and its role in obesity","volume":"234","author":"Xue","year":"2019","journal-title":"J Cell Physiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cytogfr.2026.03.002","article-title":"Chemokines in thyroid cancer: Mechanistic insights and clinical implications","volume":"89","author":"Bratborska","year":"2026","journal-title":"Cytokine Growth factor Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156504","article-title":"Atypical chemokine receptors in cancer","volume":"176","author":"Samus","year":"2024","journal-title":"Cytokine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","article-title":"CCL5\/CCR5 axis in human diseases and related treatments","volume":"9","author":"Zeng","year":"2022","journal-title":"Genes Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1124\/pharmrev.124.001361","article-title":"International Union of Basic and Clinical Pharmacology. CXVIII. Update on the nomenclature for atypical chemokine receptors, including ACKR5","volume":"77","author":"Chevign\u00e9","year":"2025","journal-title":"Pharmacol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.01.026","article-title":"Th17 cells regulate the production of CXCL1 in breast cancer","volume":"56","author":"Ma","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225703","article-title":"Silencing CTNND1 mediates triple-negative breast cancer bone metastasis via upregulating CXCR4\/CXCL12 axis and neutrophils infiltration in bone","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01758-w","article-title":"CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity","volume":"40","author":"Kim","year":"2021","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.23812\/10.23812\/19-512-a-38","article-title":"Mechanism of Jinrong granule in inhibiting the invasion of breast cancer cells by the CXCL-1-CXCR2\/CCL20 pathway","volume":"34","author":"Guo","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134290","article-title":"MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC","volume":"5","author":"Franklin","year":"2020","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4760-8","article-title":"MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis","volume":"170","author":"Dutta","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013027","article-title":"Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8(+) T cells","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25389","article-title":"The TGF\u03b1-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells","volume":"9","author":"Ignacio","year":"2018","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12032-025-02705-5","article-title":"CXCR4\/CXCL12 blockade therapy; a new horizon in TNBC therapy","volume":"42","author":"Khaleel","year":"2025","journal-title":"Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405399","article-title":"CCL20\/CXCL5 drives crosstalk between anaplastic thyroid cancer stem cells and tumor-associated macrophages to promote tumor progression","volume":"12","author":"Liu","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-36667-4","article-title":"Tumor microenvironment the role of chemokines \u2013 part a: the role of chemokines \u2013 part a","volume":"1231","author":"Birbrair","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207619","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218412","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501791122","article-title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy","volume":"122","author":"Lugassy","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20892","article-title":"A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment","volume":"8","author":"Ryan","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.02.26","article-title":"Complicated prognostic values of CCL28 in breast cancer by subtype","volume":"11","author":"Gong","year":"2019","journal-title":"J Thorac Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5089371","article-title":"CXCL1 clone evolution induced by the HDAC inhibitor belinostat might be a favorable prognostic indicator in triple-negative breast cancer","volume":"2021","author":"Han","year":"2021","journal-title":"BioMed Res Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.08.012","article-title":"Tumor entrained neutrophils inhibit seeding in the premetastatic lung","volume":"20","author":"Granot","year":"2011","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722916","article-title":"CCL2: an important mediator between tumor cells and host cells in tumor microenvironment","volume":"11","author":"Jin","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3074-2","article-title":"The Yin\/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo","volume":"17","author":"Lavender","year":"2017","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.08.008","article-title":"CX3CL1: a key switch of cell death immunogenicity","volume":"11","author":"Demuynck","year":"2025","journal-title":"Trends Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143459","article-title":"Tumor extracellular vesicles regulate macrophage-driven metastasis through CCL5","volume":"13","author":"Rabe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m109.035899","article-title":"Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone","volume":"284","author":"Lu","year":"2009","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"19150","DOI":"10.1038\/s41598-019-55702-w","article-title":"Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis","volume":"9","author":"Ryan","year":"2019","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"103205","DOI":"10.1016\/j.arcmed.2025.103205","article-title":"Significance of the monocyte CCR2-CCL2 axis in triple-negative breast cancer","volume":"56","author":"Budzy\u0144","year":"2025","journal-title":"Arch Med Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12964-022-00888-2","article-title":"Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2\/AKT\/beta-catenin signaling","volume":"20","author":"Chen","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9885","article-title":"Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment","volume":"7","author":"Fang","year":"2016","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"16351","DOI":"10.1038\/s41598-019-52746-w","article-title":"Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling","volume":"9","author":"Kalpana","year":"2019","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045877","article-title":"Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner","volume":"7","author":"Reed","year":"2012","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7420","article-title":"CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells","volume":"15","author":"Jayaraman","year":"2018","journal-title":"Oncol Lett"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1038\/s41598-018-23099-7","article-title":"Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer","volume":"8","author":"Araujo","year":"2018","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4690","article-title":"Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9(+) T cells","volume":"6","author":"Chen","year":"2020","journal-title":"Sci Adv"},{"key":"B59","article-title":"Blockade of CCL2 expression overcomes intrinsic PD-1\/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer","volume":"10","author":"Choi","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbab020","article-title":"CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration","volume":"4","author":"Ma","year":"2021","journal-title":"Precis Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.devcel.2025.08.003","article-title":"Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer","volume":"61","author":"Xing","year":"2026","journal-title":"Dev Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.07.049","article-title":"Controlled delivery of C-C motif chemokine ligand 25 by a hydrogel for tumor microenvironment remodeling in triple negative breast cancer","volume":"203","author":"Guan","year":"2025","journal-title":"Acta Biomater"},{"key":"B64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s43556-025-00306-2","article-title":"Single-cell RNA sequencing identifies CD8Teff cell activation as a predictive biomarker in triple-negative breast cancer immunotherapy","volume":"6","author":"Mao","year":"2025","journal-title":"Mol BioMed"},{"key":"B65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-026-00903-6","article-title":"The CXCL10\/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer","volume":"12","author":"Yilmaz","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.07.003","article-title":"A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth","volume":"30","author":"Han","year":"2022","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1568865","article-title":"The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge","volume":"12","author":"Brogna","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13050","article-title":"Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers","volume":"7","author":"Allaoui","year":"2016","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040991","article-title":"Oncogenic linear collagen VI of invasive breast cancer is induced by CCL5","volume":"9","author":"Brett","year":"2020","journal-title":"J Clin Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0080-7","article-title":"Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-alpha and the NF-kappaB pathway","volume":"6","author":"Katanov","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.01.039","article-title":"Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth","volume":"343","author":"Shen","year":"2022","journal-title":"J Control Release"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115193","article-title":"Antigen-presenting CAFs orchestrate immunosuppressive niches via CXCL13-mediated immune cell infiltration dysregulation and prognostic stratification in triple-negative breast cancer","volume":"162","author":"Tian","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5447.2098","article-title":"Chemokines and cell migration in secondary lymphoid organs","volume":"286","author":"Cyster","year":"1999","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nm1643","article-title":"Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/thno.59056","article-title":"CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors","volume":"11","author":"Shi","year":"2021","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-4094","article-title":"Cellular constituents of immune escape within the tumor microenvironment","volume":"72","author":"Kerkar","year":"2012","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.imlet.2009.09.003","article-title":"Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth","volume":"127","author":"Lin","year":"2010","journal-title":"Immunol Lett"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506518","article-title":"Tumor-derived CDC37 inhibits antigen cross-presentation in dendritic cells and impairs anti-tumor immunity in breast cancer","volume":"13","author":"Wang","year":"2026","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/jf504934m","article-title":"6-shogaol, an active constituent of dietary ginger, impairs cancer development and lung metastasis by inhibiting the secretion of CC-chemokine ligand 2 (CCL2) in tumor-associated dendritic cells","volume":"63","author":"Hsu","year":"2015","journal-title":"J Agric Food Chem"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/srep30207","article-title":"Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells","volume":"6","author":"Hwang","year":"2016","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li","year":"2020","journal-title":"Mol Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.34133\/research.0915","article-title":"Gene signature-based drug screening reveals ponatinib enhances immunotherapy efficacy in triple-negative breast cancer by reversing MDSC-mediated immunosuppressive tumor microenvironment","volume":"8","author":"Wang","year":"2025","journal-title":"Research"},{"key":"B86","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","article-title":"Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy","volume":"15","author":"Ciavattone","year":"2025","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-2913","article-title":"Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity","volume":"77","author":"Ban","year":"2017","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301764RR","article-title":"MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer","volume":"38","author":"Gu","year":"2024","journal-title":"FASEB J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1804280","article-title":"Clinical and therapeutic implications of cancer stem cells","volume":"380","author":"Clarke","year":"2019","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-2741","article-title":"Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature","volume":"69","author":"Charafe-Jauffret","year":"2009","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1172\/jci39397","article-title":"CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts","volume":"120","author":"Ginestier","year":"2010","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005869","article-title":"CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer","volume":"16","author":"Chen","year":"2018","journal-title":"PloS Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6234","article-title":"Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling","volume":"6","author":"Brandolini","year":"2015","journal-title":"Oncotarget"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.7150\/thno.51000","article-title":"CCL16 maintains stem cell-like properties in breast cancer by activating CCR2\/GSK3beta\/beta-catenin\/OCT4 axis","volume":"11","author":"Shen","year":"2021","journal-title":"Theranostics"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689286","article-title":"The C-X-C motif chemokine ligand 1 sustains breast cancer stem cell self-renewal and promotes tumor progression and immune escape programs","volume":"9","author":"Ciummo","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s174329","article-title":"CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00985-2","article-title":"Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer","author":"Thangavel","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8336","article-title":"Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5","volume":"7","author":"D'Esposito","year":"2016","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjad025","article-title":"CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway","volume":"15","author":"He","year":"2023","journal-title":"J Mol Cell Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1039\/d0nh00588f","article-title":"Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horiz"},{"key":"B102","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13046-020-01666-z","article-title":"Cancer-associated adipocytes: emerging supporters in breast cancer","volume":"39","author":"Zhao","year":"2020","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110734","article-title":"CCL2\/ACKR2 interaction participate in breast cancer metastasis especially in patients with altered lipid metabolism","volume":"158","author":"Zhong","year":"2021","journal-title":"Med Hypotheses"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.65227","article-title":"Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF\/CXCLs positive feedback loop","volume":"18","author":"Zhou","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B105","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41420-025-02713-4","article-title":"Adipocyte-derived IL6 and triple-negative breast cancer cell-derived CXCL1 co-activate STAT3\/NF-\u03baB pathway to mediate the crosstalk between adipocytes and triple-negative breast cancer cells","volume":"11","author":"Ruan","year":"2025","journal-title":"Cell Death Discov"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133501","article-title":"Three-dimensional breast cancer model to investigate CCL5\/CCR1 expression mediated by direct contact between breast cancer cells and adipose-derived stromal cells or adipocytes","volume":"15","author":"Watzling","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41419-023-06230-z","article-title":"Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy","volume":"14","author":"Huang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700237rr","article-title":"Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling","volume":"32","author":"Zhang","year":"2018","journal-title":"FASEB J"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659996","article-title":"Triple-negative breast cancer cells recruit neutrophils by secreting TGF-beta and CXCR2 ligands","volume":"12","author":"SenGupta","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"217692","DOI":"10.52843\/cassyni.y8p3s8","article-title":"TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells","volume":"620","author":"Kundu","year":"2025","journal-title":"Cancer Lett"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073143","article-title":"CXCR2-dependent infiltration of tumor-associated neutrophils is linked to enhanced CD8(+) T cell effector function and reduced lung metastasis in 4T1 breast cancer","volume":"27","author":"Li","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s0014-5793(03)00824-x","article-title":"T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer","volume":"550","author":"Tamamura","year":"2003","journal-title":"FEBS Lett"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.023275","article-title":"Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model","volume":"9","author":"Tulotta","year":"2016","journal-title":"Dis Model Mech"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2008.06.044","article-title":"A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer","volume":"155","author":"Huang","year":"2009","journal-title":"J Surg Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000282","article-title":"Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone","volume":"21","author":"Richert","year":"2009","journal-title":"Oncol Rep"},{"key":"B116","article-title":"AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells","volume":"1","author":"Greco","year":"2011","journal-title":"Am J Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2018.01.009","article-title":"CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation","volume":"418","author":"Zhou","year":"2018","journal-title":"Cancer Lett"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105606","article-title":"Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer","volume":"157","author":"Lu","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5b00653","article-title":"CXCR4-targeted nanocarriers for triple negative breast cancers","volume":"16","author":"Misra","year":"2015","journal-title":"Biomacromolecules"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s90082","article-title":"Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer","volume":"9","author":"Liang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2014.06.018","article-title":"Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells","volume":"21","author":"Wang","year":"2014","journal-title":"Phytomedicine"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.apsb.2025.06.012","article-title":"A dual-targeting peptide-drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.284","article-title":"CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients","volume":"36","author":"Lefort","year":"2017","journal-title":"Oncogene"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215944","article-title":"CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer","volume":"551","author":"Xie","year":"2022","journal-title":"Cancer Lett"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0252","article-title":"CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer","volume":"14","author":"Xiang","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-019-00589-w","article-title":"Carrier-free CXCR4-targeted nanoplexes designed for polarizing macrophages to suppress tumor growth","volume":"12","author":"Deci","year":"2019","journal-title":"Cell Mol Bioeng"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.029","article-title":"Star\" miR-34a and CXCR4 antagonist based nanoplex for binary cooperative migration treatment against metastatic breast cancer","volume":"326","author":"Yang","year":"2020","journal-title":"J Control Release"},{"key":"B128","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/ncomms5715","article-title":"Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis","volume":"5","author":"Lee","year":"2014","journal-title":"Nat Commun"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01391-1","article-title":"Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy","volume":"23","author":"Jiao","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112654","article-title":"ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression","volume":"42","author":"Zhang","year":"2023","journal-title":"Cell Rep"},{"key":"B131","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","article-title":"CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer","volume":"42","author":"Pervaiz","year":"2019","journal-title":"Cell Oncol (Dordr)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216635","article-title":"A novel antagonist of the CCL5\/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation","volume":"583","author":"Chen","year":"2024","journal-title":"Cancer Lett"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400146","article-title":"N-[4-(Benzyloxy)-3-methoxybenzyl)]adamantane-1-amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer","volume":"358","author":"Rostom","year":"2025","journal-title":"Arch Pharm (Weinheim)"},{"key":"B134","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-018-0981-3","article-title":"Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis","volume":"20","author":"Jin","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12918-017-0445-x","article-title":"An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia","volume":"11","author":"Norton","year":"2017","journal-title":"BMC Syst Biol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581459","article-title":"HEYL regulates neoangiogenesis through overexpression in both breast tumor epithelium and endothelium","volume":"10","author":"Han","year":"2020","journal-title":"Front Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862125","article-title":"CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer","volume":"13","author":"Ghallab","year":"2022","journal-title":"Front Pharmacol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1159\/000545659","article-title":"Inhibition of interleukin-8\/C-X-C chemokine receptor 2 signaling axis prevents tumor growth and metastasis in triple-negative breast cancer cells","volume":"110","author":"Jeong","year":"2025","journal-title":"Pharmacology"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3944","article-title":"Intratumoral plasmid IL12 expands CD8(+) T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy","volume":"27","author":"Telli","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-3186","article-title":"Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma","volume":"18","author":"Correale","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-89","article-title":"Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma","volume":"6","author":"Somovilla-Crespo","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201805182","article-title":"Locally trapping the C-C chemokine receptor type 7 by gene delivery nanoparticle inhibits lymphatic metastasis prior to tumor resection","volume":"15","author":"An","year":"2019","journal-title":"Small"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039706","article-title":"Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor","volume":"7","author":"Bangsgaard","year":"2012","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.669","article-title":"IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis","volume":"181","author":"Skov","year":"2008","journal-title":"J Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94296","article-title":"Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer","volume":"2","author":"Dominguez","year":"2017","journal-title":"JCI Insight"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-4524-t","article-title":"Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8","volume":"73","author":"Hartman","year":"2013","journal-title":"Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201858","article-title":"Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: opportunity for combination therapy","volume":"13","author":"Uddin","year":"2018","journal-title":"PloS One"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.06.009","article-title":"Cxcl8 facilitates the survival and paclitaxel-resistance of triple-negative breast cancers","volume":"22","author":"Yi","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.1038\/s41598-017-09040-4","article-title":"Human antigen R-regulated ccl20 contributes to osteolytic breast cancer bone metastasis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109488","article-title":"Cxcl12-cxcl4 heterodimerization prevents cxcl12-driven breast cancer cell migration","volume":"66","author":"Nguyen","year":"2020","journal-title":"Cell Signal"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.021","article-title":"A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis","volume":"25","author":"Su","year":"2014","journal-title":"Cancer Cell"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.01.028","article-title":"Let-7a mimic attenuates ccl18 induced breast cancer cell metastasis through lin 28 pathway","volume":"78","author":"Wang","year":"2016","journal-title":"BioMed Pharmacother"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3098","article-title":"Microrna let-7a suppresses breast cancer cell migration and invasion through downregulation of c-c chemokine receptor type 7","volume":"14","author":"Kim","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1039\/c9tb01610d","article-title":"A self-assembled rna-triple helix hydrogel drug delivery system targeting triple-negative breast cancer","volume":"8","author":"Ding","year":"2020","journal-title":"J Mater Chem B"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233992","article-title":"Mir-205 regulates tamoxifen resistance by targeting estrogen receptor coactivator med1 in human breast cancer","volume":"16","author":"Ouyang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.12.051","article-title":"Mir-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting cxcr4","volume":"86","author":"Xue","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3638","article-title":"Emodin inhibits epithelial-mesenchymal transition and metastasis of triple negative breast cancer via antagonism of cc-chemokine ligand 5 secreted from adipocytes","volume":"42","author":"Song","year":"2018","journal-title":"Int J Mol Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116335","article-title":"Cxcr4 expression is elevated in tnbc patient derived samples and z-guggulsterone abrogates tumor progression by targeting cxcl12\/cxcr4 signaling axis in preclinical breast cancer model","volume":"232","author":"Gupta","year":"2023","journal-title":"Environ Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051959","article-title":"Triterpenes of prunella vulgaris inhibit triple-negative breast cancer by regulating ptp1b\/pi3k\/akt\/mtor and il-24\/cxcl12\/cxcr4 pathways","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11240","article-title":"Molecular mechanism of gossypol mediating ccl2 and il-8 attenuation in triple-negative breast cancer cells","volume":"22","author":"Messeha","year":"2020","journal-title":"Mol Med Rep"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176076","article-title":"Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages","volume":"959","author":"Mei","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7674","article-title":"Potential anticancer effect of prostratin through sik3 inhibition","volume":"15","author":"Alotaibi","year":"2018","journal-title":"Oncol Lett"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0222-6","article-title":"Ginsenoside rg3 inhibits cxcr4 expression and related migrations in a breast cancer cell line","volume":"16","author":"Chen","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01487","article-title":"Saikosaponin a inhibits triple-negative breast cancer growth and metastasis through downregulation of cxcr4","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172794","article-title":"Targeting the tumor immune microenvironment in triple-negative breast cancer: The promise of polyphenols","volume":"17","author":"Hilliard","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B166","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1038\/s41598-021-85090-z","article-title":"Pentagalloyl glucose inhibits tnf-alpha-activated cxcl1\/gro-alpha expression and induces apoptosis-related genes in triple-negative breast cancer cells","volume":"11","author":"Mendonca","year":"2021","journal-title":"Sci Rep"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109519","article-title":"XIAOPI formula promotes breast cancer chemosensitivity via inhibiting cxcl1\/hmgb1-mediated autophagy","volume":"120","author":"Wang","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156039","article-title":"XIAOPI formula inhibits chemoresistance and metastasis of triple-negative breast cancer by suppressing extracellular vesicle\/cxcl1-induced tam\/pd-l1 signaling","volume":"135","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0411-z","article-title":"Crkl regulates sdf-1-induced breast cancer biology through balancing erk1\/2 and pi3k\/akt pathways","volume":"32","author":"Lian","year":"2015","journal-title":"Med Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.569729","article-title":"The recombinant protein based on trypanosoma cruzi p21 interacts with cxcr4 receptor and abrogates the invasive phenotype of human breast cancer cells","volume":"8","author":"Borges","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B171","article-title":"Norepinephrine attenuates cxcr4 expression and the corresponding invasion of mda-mb-231 breast cancer cells via beta2-adrenergic receptors","volume":"19","author":"Wang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B172","unstructured":"ClinicalTrials 2026"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.e13062","article-title":"Safety, efficacy, and clinical outcomes of the anti-ccr5 inhibitor (leronlimab): A pooled analysis of three clinical trials in patients with mtnbc","volume":"40","author":"Adams","year":"2022","journal-title":"J Clin Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10238-024-01362-8","article-title":"Selective depletion of tumor-infiltrating regulatory t cells with bay 3375968, a novel fc-optimized anti-ccr8 antibody","volume":"24","author":"Roider","year":"2024","journal-title":"Clin Exp Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-020-01294-7","article-title":"Correction to: A window-of-opportunity trial of the cxcr1\/2 inhibitor reparixin in operable her-2-negative breast cancer","volume":"22","author":"Goldstein","year":"2020","journal-title":"Breast Cancer research: BCR"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.sabcs12-ot2-3-01","article-title":"Phase ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with her-2 negative metastatic breast cancer (mbc)","volume":"23","author":"Schott","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06367-5","article-title":"A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (frida)","volume":"190","author":"Goldstein","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in her2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/pancan.2019.0018","article-title":"Safety and pharmacokinetics of cxcr4 peptide antagonist, ly2510924, in combination with durvalumab in advanced refractory solid tumors","volume":"6","author":"O'Hara","year":"2020","journal-title":"J Pancreatic Cancer"},{"key":"B180","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase i trial of humax-il8 (bms-986253), an anti-il-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-c-c chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Target Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase i study of carlumab (cnto 888), a human monoclonal antibody against cc-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011323","article-title":"A missing puzzle in preclinical studies-are ccr2, ccr5, and their ligands' roles similar in obesity-induced hypersensitivity and diabetic neuropathy?-evidence from rodent models and clinical studies","volume":"25","author":"Bober","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18315","article-title":"Tumour-derived exosome snhg17 induced by oestrogen contributes to ovarian cancer progression via the ccl13-ccr2-m2 macrophage axis","volume":"28","author":"Liang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70527","article-title":"Spatiotemporal mapping reveals ccl8(hi) macrophages as key drivers of testicular inflammaging","volume":"15","author":"Huang","year":"2025","journal-title":"Clin Transl Med"},{"key":"B186","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12964-025-02550-z","article-title":"Fusobacterium nucleatum-reprogrammed adipocytes promote tumor cisplatin resistance through the ccl2-ccr2 axis in the necrotic metastatic neck nodes of head and neck carcinoma","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5169648","article-title":"Chemokine ccl12 in trigeminal ganglion contributes to cfa-induced mechanical allodynia in mice","volume":"580","author":"Ma","year":"2025","journal-title":"Neuroscience"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500902r","article-title":"D-dopachrome tautomerase-driven astrocytic ccl7 aggravates neuropathology by recruitment of microglia following spinal cord injury","volume":"39","author":"Song","year":"2025","journal-title":"FASEB J"},{"key":"B189","doi-asserted-by":"publisher","first-page":"45256","DOI":"10.1038\/s41598-025-28988-2","article-title":"Single-cell rna sequencing revealed the association between proximal tubular epithelial cells and renal interstitial cells in chronic kidney disease progression","volume":"15","author":"Xu","year":"2025","journal-title":"Sci Rep"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332026","article-title":"Single-cell transcriptomic analysis reveals the association of ccl6+ccr2+arg1+ macrophages with renal interstitial fibrosis in aki","volume":"20","author":"Zheng","year":"2025","journal-title":"PloS One"},{"key":"B191","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218192","article-title":"Copper orchestrates triple-negative breast cancer progression via the steap3-dependent cdk16-jak1 activation","volume":"639","author":"Duan","year":"2026","journal-title":"Cancer Lett"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2014.02.006","article-title":"Chemokines and chemokine receptors: update on utility and challenges for the clinician","volume":"155","author":"Roy","year":"2014","journal-title":"Surgery"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529847","article-title":"Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction","volume":"16","author":"Verona","year":"2025","journal-title":"Front Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1620807","article-title":"Targeting csc-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy","volume":"16","author":"Yu","year":"2025","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"B197","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3892\/ol.2025.15344","article-title":"Ccl2\/ccr2 signaling pathway in tumorigenesis and metastasis (review)","volume":"30","author":"Zhang","year":"2025","journal-title":"Oncol Lett"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01390","article-title":"CCL3 enhances antitumor immune priming in the lymph node via IFNgamma with dependency on natural killer cells","volume":"8","author":"Allen","year":"2017","journal-title":"Front Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1687","article-title":"Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells","volume":"71","author":"Gonzalez-Martin","year":"2011","journal-title":"Cancer Res"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1107791","article-title":"Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice","volume":"84","author":"Iida","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay1357","article-title":"Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy","volume":"5","author":"Williford","year":"2019","journal-title":"Sci Adv"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31412","article-title":"Intratumoral gammadelta T-cell infiltrates, chemokine (C-C motif) ligand 4\/chemokine (C-C motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma","volume":"73","author":"Zhao","year":"2021","journal-title":"Hepatology"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1196299","article-title":"Macrophages promote matrix protrusive and invasive function of breast cancer cells via MIP-1beta dependent upregulation of MYO3A gene in breast cancer cells","volume":"5","author":"Baghel","year":"2016","journal-title":"Oncoimmunology"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2015.12.004","article-title":"CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer","volume":"77","author":"Ding","year":"2016","journal-title":"BioMed Pharmacother"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85841","article-title":"Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype","volume":"1","author":"Gabrusiewicz","year":"2016","journal-title":"JCI Insight"},{"key":"B206","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2017.01.003","article-title":"The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation","volume":"106","author":"Iriki","year":"2017","journal-title":"Lung Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-0441-4","article-title":"CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways","volume":"100","author":"Kodama","year":"2020","journal-title":"Lab Invest"},{"key":"B208","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41419-019-1508-2","article-title":"Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5","volume":"10","author":"Nishikawa","year":"2019","journal-title":"Cell Death Dis"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12690","article-title":"Distribution and prognostic impact of microglia\/macrophage subpopulations in gliomas","volume":"29","author":"Zeiner","year":"2019","journal-title":"Brain Pathol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000004009","article-title":"Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming","volume":"139","author":"Zhao","year":"2026","journal-title":"Chin Med J (Engl)"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.008","article-title":"Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications","volume":"86","author":"Mehraj","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1172\/jci45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B215","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-016-0690-8","article-title":"Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer","volume":"18","author":"Liu","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B216","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymeth.2025.06.007","article-title":"A prognostic gene signature and subtype-specific drug sensitivity in TNBC revealed by single-cell and bulk RNA sequencing: Insights into stemness and tumor heterogeneity","volume":"242","author":"Minh Xuan","year":"2025","journal-title":"Methods"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10469-9","article-title":"Ecotypes of triple-negative breast cancer in response to chemotherapy","volume":"654","author":"Yan","year":"2026","journal-title":"Nature"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116439","article-title":"CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer","volume":"175","author":"Li","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-026-02568-y","article-title":"piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer","volume":"25","author":"Luo","year":"2026","journal-title":"Mol Cancer"},{"key":"B220","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1101\/2025.11.01.685128","article-title":"Contribution of mesenchymal-like and epithelial cellular subsets to chemotherapy resistance in triple-negative breast cancer","volume":"27","author":"Vuong","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B221","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12943-025-02496-3","article-title":"The enhanced cancer nanovaccine by bidirectionally blocking CXCL12\/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1687190","article-title":"Harnessing oncolytic viruses to overcome immunosuppression in breast cancer: From mechanisms to clinical translation","volume":"16","author":"Xianshu","year":"2025","journal-title":"Front Immunol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.01.013","article-title":"Molecular definition of breast tumor heterogeneity","volume":"11","author":"Shipitsin","year":"2007","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1883663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:33:51Z","timestamp":1785933231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1883663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":224,"alternative-id":["10.3389\/fimmu.2026.1883663"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1883663","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1883663"}}